Beta
Trial Radar KI
enums.trial_summary.trial_summary_welcome
Eine Studie entspricht den Filterkriterien
Kartenansicht
Zurück zur Suche

Researching the Effect of Exercise on Cancer

Aktiv, nicht rekrutierend
Die Details der klinischen Studie sind hauptsächlich auf Englisch verfügbar. Trial Radar KI kann jedoch helfen! Klicken Sie einfach auf 'Studie erklären', um die Informationen zur Studie in der ausgewählten Sprache anzuzeigen und zu besprechen.
Die klinische Studie NCT04589468 ist eine interventionsstudie zur Untersuchung von Brustkrebs, Prostatakrebs, Kolorektalkrebs, Stadium I Brustkrebs, Stadium II Brustkrebs, Brustkrebs im Stadium III, Stadium I Prostatakrebs, Stadium II Prostatakrebs, Stadium III Prostatakrebs, Stadium I Darmkrebs, Stadium II Kolorektalkarzinom, Stadium III Kolorektalkrebs und hat den Status aktiv, nicht rekrutierend. Die Studie startete am 2. Oktober 2020 und soll 33 Teilnehmer aufnehmen. Durchgeführt von Memorial Sloan Kettering Krebszentrum ist der Abschluss für 2. Oktober 2026 geplant. Die Daten von ClinicalTrials.gov wurden zuletzt am 5. November 2025 aktualisiert.
Kurzbeschreibung
Researchers think that exercise may be able to prevent cancer from coming back by lowering ctDNA levels. The purpose of this study is to explore how aerobic exercise (exercise that stimulates and strengthens the heart and lungs and improves the body's use of oxygen) can reduce the level of ctDNA found in the blood. During the study, the highest level of exercise that is practical, is safe, and has positive effects on the body that may prevent the return of cancer (including a decrease in ctDNA levels) will be found. Each level of exercise tested will be a certain number of minutes each week. Once the best level of exercise is found, it will be tested further in a new group of participants. All participants in this study will have been previously treated for breast, prostate, or colorectal cancer.
Offizieller Titel

Phase 1a/b Trial of Exercise as Interception Therapy for Primary High-Risk Cancer

Erkrankungen
BrustkrebsProstatakrebsKolorektalkrebsStadium I BrustkrebsStadium II BrustkrebsBrustkrebs im Stadium IIIStadium I ProstatakrebsStadium II ProstatakrebsStadium III ProstatakrebsStadium I DarmkrebsStadium II KolorektalkarzinomStadium III Kolorektalkrebs
Weitere Studien-IDs
  • 20-378
NCT-Nummer
NCT04589468
Studienbeginn (tatsächlich)
2020-10-02
Zuletzt aktualisiert
2025-11-05
Studienende (vorauss.)
2026-10-02
Geplante Rekrutierung
33
Studientyp
Interventionsstudie
PHASE
Nicht zutreffend
Status
Aktiv, nicht rekrutierend
Stichwörter
Breast Cancer
Prostate Cancer
Colorectal Cancer
exercise
ctDNA
20-378
Memorial Sloan Kettering Cancer Center
Primäres Ziel
Prävention
Zuteilungsmethode
Nicht randomisiert
Interventionsmodell
Sequentiell
Verblindung
Keine (offene Studie)
Studienarme/Interventionen
Teilnehmergruppe/StudienarmIntervention/Behandlung
ExperimentellDose-Finding/Escalation
Fifty (n=50) post-treatment patients with colorectal cancer or breast cancer, deemed high-risk of relapse. The study will use an adaptive continuous reassessment method (CRM) design to assign patients sequentially at trial entry to one of five escalated doses depending on the feasibility / tolerability of exercise therapy evaluated over the total treatment period. The primary objective of this phase 1a trial is to identify the RP2D of exercise therapy for further evaluation in the phase 1b trial.
Übung
Exercise therapy in both phases will consist of individualized walking delivered 3 to 6 times weekly (over a 7-day period). Exercise treatment will be delivered for up to 18 months, or until progression of disease or withdrawal of consent, whichever comes first. The phase 1a trial will assess five doses of exercise therapy (i.e., 90, 150, 225, 300, and 375 mins/wk) delivered following a non-linear (i.e., exercise dose is continually altered and progressed in conjunction with appropriate rest/recovery sessions across the entire intervention period) dosing schedule. The phase 1b trial will only test one dose of exercise therapy - the RP2D identified in the phase 1a trial.
ExperimentellDose Expansion
An independent cohort of 30 post-treatment patients with colorectal (n=15) or breast (n=15) cancer deemed high-risk of relapse. This cohort expansion trial will only evaluate the RP2D identified in the phase 1a trial. The primary objective of this phase 1b trial is to further evaluate the feasibility, safety, and biological activity of the RP2D.
Übung
Exercise therapy in both phases will consist of individualized walking delivered 3 to 6 times weekly (over a 7-day period). Exercise treatment will be delivered for up to 18 months, or until progression of disease or withdrawal of consent, whichever comes first. The phase 1a trial will assess five doses of exercise therapy (i.e., 90, 150, 225, 300, and 375 mins/wk) delivered following a non-linear (i.e., exercise dose is continually altered and progressed in conjunction with appropriate rest/recovery sessions across the entire intervention period) dosing schedule. The phase 1b trial will only test one dose of exercise therapy - the RP2D identified in the phase 1a trial.
Hauptergebnismessungen
ErgebnismessungBeschreibung der MessungZeitrahmen
Identify the recommended phase 2 dose (RP2D) of exercise for testing in the phase 1b.
Using an adaptive phase 1 (non-randomized) design, non-exercising (i.e., \<60 mins/wk of moderate or vigorous exercise) post-treatment patients with primary breast, prostate, or colorectal cancer and detectable ctDNA (n=50) will be administered one of five escalating dose levels.
24 weeks
Eignungskriterien

Zugelassene Altersgruppen
Erwachsene, Ältere Erwachsene
Mindestalter
18 Years
Zugelassene Geschlechter
Alle

  • Postsurgical diagnosis of patients with primary solid tumors at high-risk of relapse as defined by one of the following:

    ° High-risk primary solid tumor (e.g., colorectal, ovarian, non-small cell lung cancer) (colorectal cancer only for Phase 1a)

  • Stage 3 or

  • ctDNA positive

    ° High-risk breast cancer

  • Residual invasive disease in the breast or the lymph nodes following completion of neoadjuvant chemotherapy (NACT),

  • Estrogen receptor (ER), and/or progesterone receptor (PR) positive and HER2 negative,

  • CPS-EG score ≥ 3,

  • CPS-EG score ≥2 w ith ypN+, or

  • Recurrence score ≥ 25

  • No evidence of disease

  • Age ≥ 18

  • Interval of ≥ 1 month but ≤ 2 years following completion of all definitive adjuvant therapy

  • Non-exercising (i.e., < 30 minutes of moderate and < 20 mins of vigorous exercise/wk), as assessed by remote activity and heart rate tracking for a 7-day period prior to study entry)

    ° If ≥ 30 minutes but less than 45 minutes of moderate exercise/week, or if ≥ 20 minutes but less than 30 minutes of vigorous exercise/week, patients may be eligible, at the discretion of the PI.

  • Cleared for exercise participation as per screening clearance via PAR-Q+

  • Willingness to comply with all study-related procedures

  • Enrollment onto any other interventional investigational study except interventions determined by the PI not to confound study outcomes
  • Any other current diagnosis of invasive cancer of any kind
  • Distant metastatic malignancy of any kind
  • Any other condition or intercurrent illness that, in the opinion of the investigator, makes the subject a poor candidate for study participation
Memorial Sloan Kettering Cancer Center logoMemorial Sloan Kettering Krebszentrum739 aktive klinische Studien zum Erkunden
Keine Kontaktdaten vorhanden
8 Studienstandorte in 1 Ländern

California

Natera, Inc. (Data or Specimen Analysis Only), San Carlos, California, 94070, United States

New Jersey

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, 07920, United States
Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, 07748, United States
Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, 07645, United States

New York

Memorial Sloan Kettering Commack (Limited Protocol Activities), Commack, New York, 11725, United States
Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison, New York, 10604, United States
Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States
Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale, New York, 11553, United States